Hepatit B virüsü ile enfekte sağlıklı taşıyıcılarda hepatit B virüs yüzey antijeni ile intradermal aşı tedavisi

Amaç: Bu çalışmada, sağlıklı hepatit B taşıyıcılığında intradermal hepatit B aşısı uygulaması ile hepatit B yüzey antijenlerine karşı antikor oluşumunun araştırılması amaçlanmıştır. Yöntem: 0, 3, 7, 14, 28. günlerde, 30 sağlıklı hepatit B taşıyıcısına rekombinant hepatit B aşısı (H-B Vax II) intradermal olarak ön kol dorsal yüze uygulandı. Kontrol grubu olarak 30 olgu tedavisiz izlendi. Bulgular: Aşılama sonucunda tedavi grubunda bir olguda HBsAg negatifleşti, kontrol grubunda bir olguda HBsAg negatifleşti ve anti-HBs antikoru gelişti. Transaminaz değerlerinde her iki grupta da istatistiksel olarak anlamlı değişiklik saptanmadı. Kontrol grubu ile karşılaştırıldığında çalışma grubunda istatistiksel olarak anlamlı bir anti-HBs antikor yanıtı oluşmadı. Sonuç: Kronik hepatit B'de aşı tedavisi başarılı sonuçlar alınmasına rağmen, sağlıklı hepatit B taşıyıcılığında başarılı olunamaması her iki klinik durumun immünopatogenezinin farklılığından kaynaklanıyor olabilir.

Intradermal vaccine therapy with hepatitis B surface antigen in healthy hepatitis B virus infected patients

Objective: The aim of this study was to determine whether hepatitis B vaccination could elicit antibody response against hepatitis B surface antigen in healthy hepatitis B carriers. Methods: Thirty healthy hepatitis B virus (HBV) carriers were vaccinated with hepatitis B vaccine (H-B Vax II) on days 0,3,7,14, and 28 consecutively by intradermal route on the dorsal side of the forearm. The control group was elucidated from 30 healthy HBV carriers and observed without any vaccination. Results: In the therapy group, in one patient has become negative, in the control group, one patient has become positive for antibody against hepatitis B surface antigen (anti-HBs). There was no statistically significant difference between the two groups with respect to transaminase levels. There was also no statistically significant difference between therapy and control group according to the anti-HBs response. Conclusion: The reason for failure of anti-HBs seroconversion after vaccination in healthy HBV carriers in contrast to the success obtained in chronic B hepatitis patients can be explained by the difference in the immunopathogenesis of the two clinical conditions.

___

  • Beasley RP. Hepatitis B virus. The major etiology of hepatocellular carcinoma. Cancer 1988;61:1942-56.
  • Milich DR, Jones JE, Hughes JL, Price J, Raney AK, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunologic tolerance in utero? Proc Natl Acad Sci USA 1990;87:6599-603.
  • Kılıçturgay K. Viral Hepatitte İmmünopatogenez. In: Kılıçturgay K (ed). Viral Hepatit’98, 1. Baskı, İstanbul: Viral Hepatitle Savaşım Derneği, 1998:238-45.
  • Bertoletti A, Southwood S, Chesnut R, Sette A, Falco M, Ferrara GB, et al. Molecular features of the hepatitis B virus nucleocapsid T cell epitope 18-27: Interaction with HLA and T-cell receptor. Hepatology 1997;26:1027-34.
  • Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
  • Feitelson MA, Duan LX. Hepatitis B virus X antigen in the pathogenesis of chronic infections and the development of hepatocellular carcinoma. Am J Pathol 1997;150:1141-57.
  • Kurt H. Klinik Bulgular. In: Kılıçturgay K (ed). Viral Hepatit’98, 1. Baskı, İstanbul: Viral Hepatitle Savaşım Derneği, 1998:101-6.
  • Pol S, Couillin I, Michel ML, Driss F, Nalpas B, Carnot F, et al. Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Acta Gastroenterol Belg 1998; 6:228-33.
  • Fruttaldo L, Schettino G, Mongio F. Anti-HBV vaccination before therapy with interferon (IFN) in chronic B hepatitis. Eur Rev Med Pharmacol Sci 1997;1:197-201.
  • Akbar SM, Kajino K, Tanimoto K, Kurose K, Masumoto T, Michitaka K, et al. Placebo controlled trial of vaccination with hepatitis B virus surface antigen in hepatitis B virus transgenic mice. J Hepatol 1997;26:131-37.
  • Hervas-Stubbs S, Lasarte JJ, Sarobe P, Prieto J, Cullen J, Roggendorf M, et al. Therapeutic vaccination of woodchucks against chronic woodchuck hepatitis virus infection. J Hepatol 1997; 27:726-37.
  • Şentürk H, Tabak F, Akdoğan M, et al. Therapeutic vaccination with a pre S2 containing vaccine in chronic hepatitis B: A promising approach. Hepatology 1998;28 (Suppl): 588A.
  • Wen YM, Wu XH, Hu DC, Zhang QP, Guo SQ. Hepatitis B vaccine and anti-HBs complex as approach for vaccine therapy. Lancet 1995;345:1575-76.
  • Dienstag JL, Stevens CE, Bhan AK, Szmuness W. Hepatitis B vaccine administered to chronic carriers of hepatitis B surface antigen. Ann Intern Med 1982;96:575-79.
  • Pol S. Immunotherapy of chronic hepatitis B by anti-HBV vaccine. Biomed Pharmacother 1995;49:105-9.
  • Chutivongse S, Wilde H, Supich C, Baer GM, Fishbein DB. Postexposure prophylaxis for rabies with antiserum and intradermal vaccination. Lancet 1990;335:896-8.
  • Briggs DJ, Banzhoff A, Nicolay U, Sirikwin S, Dumavibhat B, Tongswas S, et al. Antibody response of patients after postexposure rabies vaccination with small intradermal doses of purified chick embryo cell vaccine or purified Vero cell rabies vaccine. Bull World Health Organ 2000;78:693-8.
  • Suntharasamai P, Chaiprasithikul P, Wasi C, Supanaranond W, Auewarakul P, Chanthavanich P, et al. A simplified and economical intradermal regimen of purified chick embryo cell rabies vaccine for postexposure prophylaxis. Vaccine 1994; 12:508-12.
  • Charanasri U, Meesomboon V, Kingnate D, Samuthananont P, Chaeychomsri W. Intradermal simulated rabies postexposure prophylaxis using purified chick embryo rabies vaccine. J Med Assoc Thai 1994; 77:157-60.